Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silo Pharma Inc SILO

Healthcare Psychedelics
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and... see more

Recent & Breaking News (NDAQ:SILO)

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

GlobeNewswire 13 days ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

GlobeNewswire January 2, 2025

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

GlobeNewswire December 18, 2024

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

GlobeNewswire November 29, 2024

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

GlobeNewswire November 18, 2024

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

GlobeNewswire October 31, 2024

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

GlobeNewswire September 10, 2024

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

GlobeNewswire August 14, 2024

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

GlobeNewswire August 7, 2024

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

GlobeNewswire July 26, 2024

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire July 22, 2024

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire July 19, 2024

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

GlobeNewswire July 18, 2024

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

GlobeNewswire July 16, 2024

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

GlobeNewswire July 8, 2024

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

GlobeNewswire June 26, 2024

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

GlobeNewswire June 7, 2024

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 6, 2024

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 5, 2024

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

GlobeNewswire June 4, 2024